MeSH D015464 - bcr-abl positive chronic myelogenous leukemia
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| Teva | Idarubicin | Idarubicin |  | 2002-05-01 |  |  |
| Imatinib | Imatinib Teva |  | 2013-01-07 |  |  | |
| Cyclophosphamide | Neosar |  | 1993-04-29 |  |  | |
| Imatinib | Imatinib Teva B.V |  | 2017-11-15 |  |  | |
| Dr Reddys Laboratories | Cyclophosphamide | Cyclophosphamide | 2036-02-15 | 2020-07-30 |  |  |
| Mylan | Busulfan | Busulfan |  | 2018-07-13 |  |  |
| Rising Pharmaceuticals | Idarubicin | Idarubicin |  | 2012-10-11 |  |  |
| Cipla | Cyclophosphamide | Cyclophosphamide |  | 2019-01-18 |  |  |
| Sandoz | Idarubicin | Idarubicin |  | 2011-03-29 |  |  |
| Cyclophosphamide | Cyclophosphamide |  | 2023-09-12 |  |  | |
| Novartis | Imatinib | Glivec |  | 2001-11-07 |  |  |
| Asciminib | Scemblix |  | 2022-08-25 | $599 M | Q2/22-Q2/25 | |
| Nilotinib | Tasigna |  | 2007-11-19 | $1,747 M | Q2/22-Q2/25 | |
| Merck & Co | Interferon alfa-2b | Intron A |  | 1986-06-04 |  |  |
| Interferon alfa-2b | IntronA |  | 2000-03-09 |  |  | |
| Interferon alfa-2b | Viraferon |  | 2000-03-09 |  |  | |
| Pfizer | Bosutinib | Bosulif |  | 2013-03-27 | $645 M | Y2023 |
| Idarubicin | Idamycin |  | 1990-09-27 |  |  | |
| Barr Pharmaceuticals | Hydroxyurea | Hydroxyurea |  | 1998-07-30 |  |  |
1
2
3
4
5
>
Clinical Trials
Historical Success Rate
Phase 1
53%85/159
Phase 2
32%39/122
Phase 3
39%22/56
Approved: 13Overall Success rate: 7%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
1
2
3
4
>
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use